MYCN Amplification Is Associated with Reduced Expression of Genes Encoding γ-Secretase Complex and NOTCH Signaling...

Area of Science:

• Molecular Oncology
• Neuroblastoma Pathogenesis
• Gene Regulation

Background:

• MYCN oncogene amplification is a hallmark of high-risk neuroblastoma (NB), associated with poor prognosis.
• The precise molecular mechanisms by which MYCN drives aggressive NB remain incompletely understood.
• Understanding MYCN's regulatory network is crucial for developing targeted therapies.

Purpose of the Study:

• To identify biological processes directly regulated by MYCN in neuroblastoma.
• To elucidate the role of MYCN in the molecular circuitry of high-risk NB.
• To investigate the impact of MYCN on the NOTCH signaling pathway.

Main Methods:

• Integrative analysis of RNA-Seq and MYCN ChIP-Seq datasets from human NB cell lines.
• Comparison of gene expression profiles between MYCN-amplified and non-amplified NB cells.
• Analysis of MYCN binding sites and validation in primary NB tumor datasets.

Main Results:

• MYCN-amplified NB cells exhibit reduced expression of genes involved in NOTCH receptor processing and γ-secretase complex.
• MYCN directly binds to the transcription start sites of γ-secretase subunit genes.
• Reduced γ-secretase and NOTCH pathway gene expression in MYCN-amplified tumors correlates with worse patient survival.

Conclusions:

• MYCN actively suppresses the expression of γ-secretase complex genes in neuroblastoma.
• This suppression impacts NOTCH-target gene expression, contributing to high-risk NB phenotypes.
• The study identifies a novel MYCN-driven regulatory axis with implications for NB treatment strategies.